FREE Daily Stock Alerts From Stock-PR.com
Proteonomix, Inc. (OTCPK:PROT)
PROT, a biotechnology company, engages in the development of stem cell therapies primarily for the treatment of diabetes and cardiac therapy, as well as offers cosmeceutical products. The stem cell therapy involves the introduction of healthy new stem cells to repair and replace damaged or lost cells. PROT offers product for the treatment of anti-aging and damaged skin. PROT develops cosmetic products using its technologies, Secreted Matrix and Matrix NC-138 that is a stem cell derived proteins technology. PROT is also involved in the operation of retail Web site, Proteoderm.com to sell its anti-aging line of skin care products; develops therapeutic modalities for the treatment of cardiovascular disease; and engages in the reproductive tissue banking, including sperm, ova, ovarian tissue, and testicular tissue. In addition, PROT develops intellectual properties for patent applications, including a medium and scaffolding for enhancing the growth of stem cells, a growth platform for stem cells, a cord blood banking cryopreservation bag, and a device to eliminate malformed stem cells via filtration. Further, PROT is developing pre-clinical-stage therapeutic agents and treatments for cancer, diabetes, heart, lung, and kidney diseases, as well as for stem cell bone marrow and organ transplants. PROT was formerly known as National Stem Cell Holding, Inc. and changed its name to Proteonomix, Inc. in August 2008. PROT was founded in 2005 and is based in Mountainside, New Jersey.
PROT announced that it has filed a utility patent application for the Preparation and Use of Stromal Cells for Treatment of Cardiac Diseases.
Michael Cohen, President of PROT, stated: “This is another step in the development of our intellectual property and getting StromaCel into the commercial market. The technology covered by the patent application will reduce the cost to the patient of this type of treatment and when trials are completed and regulatory approvals are obtained we believe that the stromal cell technology we announce today will have major importance in the treatment of cardiac damage caused by heart attacks.”
Without going into proprietary details, Mr. Cohen noted that the application relates to cell line expansion that he believes represents a fundamental improvement in the efficiency of producing stem cells which should have applications far beyond the cardiac therapy to which the present application relates.
To learn more about PROT visit: http://www.proteonomix.com
Terex Corporation (NYSE:TEX)
TEX will release its third quarter 2010 financial results on Wednesday, October 20, 2010 after market close. TEX will host a conference call to review the financial results on Thursday, October 21, 2010 at 8:30 a.m. EDT. Ronald M. DeFeo, Chairman and CEO, will host the call.
A simultaneous webcast of this call will be available on TEX’s website, www.terex.com. To listen to the call, select “Investor Relations” in the “About Terex” section on the home page and then click on the webcast microphone link. Participants are encouraged to access the call 10 minutes prior to the starting time. The call will also be archived on TEX’s website under “Audio Archives” in the “Investor Relations” section of the website.
Ternium S.A. (NYSE:TX)
TX and Nippon Steel Corporation announced recently that they have signed a definitive agreement to form a joint venture in Mexico for the manufacturing and sale of hot-dip galvanized and galvannealed steel sheets to serve the Mexican automobile market. The joint venture will operate under the name of Tenigal SRL de CV (Tenigal). TX and Nippon Steel will hold 51% and 49% participations in Tenigal, respectively.
Tenigal plans to build a hot-dip galvanizing plant in the vicinity of Monterrey City (equivalent to the state-of-the-art equipment now in operation at Nippon Steel's steelworks in Japan) with a production capacity of 400,000 metric tons per year. Construction of the facility would require a total investment of approximately US$350 million. The plant is expected to commence production of high-grade and high-quality galvanized and galvannealed automotive steel sheets, including outer-panel and high-strength qualities, in 2013.
Terra Nova Royalty Corporation (NYSE:TTT)
TTT announced that it has entered into an agreement with Mass Financial Corp. ("Mass") for TTT to acquire all of the issued and outstanding shares of Mass by way of a take-over bid (the "Offer"). The Offer is one TTT share for each Mass share, valuing the transaction at approximately $225 million. The Offer is based upon the adjusted book value of each company and values TTT shares at $8.91 per share. All monetary amounts herein are in U.S. dollars.
Mass's business encompasses a broad spectrum of activities related to the integrated combination of commodities and natural resources, including trading, commercial trade, proprietary investing and financial services.
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!
Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. Stock-PR.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold Stock-PR.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://stock-pr.com/disclaimer).Crown Equity Holdings Inc. (OTCPK:CRWE) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (OTCPK:CRWE), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (OTCPK:CRWE) advertises for a particular client, Crown Equity Holdings Inc. (OTCPK:CRWE) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (OTCPK:CRWE), if paid in stock, can and may sell those securities during the advertising period.Crown Equity Holdings Inc. (OTCPK:CRWE) has received twenty thousand dollars in cash and twenty thousand dollars in free trading shares from a third party (Swiss Financial Report) for (30) days of advertisement services for Proteonomix, Inc. (OTCPK:PROT).
Sign Up For Free Stock Alerts At http://stock-pr.com/signup
________________________________________Be Sure To Visit stock-pr.ning.com
The views expressed in any article, reports, writings are not necessarily the views of Crown Equity Holdings Inc. its officers, directors, staff, contractors or employees. They do not represent the views or opinions of this site. Views expressed in articles are those of the author alone.